Yongxin Ren
Hong Kong Baptist University(HK)Shanxi Medical University(CN)Institute of Food Science & Technology(GB)Hua Medicine (China)(CN)Jiangsu Province Hospital(CN)Nanjing Medical University(CN)
Publications by Year
Research Areas
Liver physiology and pathology, Lung Cancer Treatments and Mutations, PI3K/AKT/mTOR signaling in cancer, Neuroendocrine Tumor Research Advances, Lung Cancer Research Studies
Most-Cited Works
- → Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study(2021)202 cited
- → FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging(2017)183 cited
- → Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy(2014)151 cited
- → Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer(2014)133 cited
- → Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models(2014)119 cited